Regencell Bioscience Holdings Limited (RGC)
NEUTRALFundamental
66
मूल्य
$5.55
मार्केट कैप
-
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$3.16B
पिछले 12 महीने (31/12/2017 तक)
शुद्ध आय
$112M
पिछले 12 महीने (31/12/2017 तक)
Free Cash Flow
-
कुल इक्विटी
$-856M
कुल देनदारियाँ
$3.70B
Current Ratio
0.83
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$3.74
वर्तमान मूल्य
$5.55
Margin of Safety
-48.3%
Fair Value सीमा
$3.55 - $3.93
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
7.35
ROE
-13.1%
P/B Ratio
-
P/FCF
-
Gross Margin
-
ROIC
9.4%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
9.4%
WACC
11.6%
ROIC − WACC
-2.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (11)
- EPS shows upward trend
- EPS CAGR 18.50%
- Price CAGR 44.61%
- ROIC 9.4%
- Operating Margin 8.6%
- Current Ratio
- Return on Tangible Assets
- Low reliance on intangibles
- Earnings Quality (OCF/NI) 3.65
- Share Dilution -0.3%
- Piotroski F-Score 5/9
फेल (3)
- DCF valuation (Unknown)
- ROE -231.9%
- Net Margin Trend 3.6% vs 5.3%
अनुपलब्ध (14)
- Gross Margin NaN%
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- Analyst Consensus (Finnhub)
- Earnings Surprise (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक
Earnings गुणवत्ता
उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Yat-Gai Au | Founder, Chairman & CEO | 52 |
| Ms. Michelle Chan | Financial Controller, CFO & Principal Financial Officer | - |
| Mr. Wai Hong Chung | COO, Chief Strategy Officer & Director | 47 |
| Ms. Antonia Assang | Senior Vice President of Project Management | - |
| Mr. Yat-Pui Au | Chief Business Officer | 50 |
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for RGC, sourced from Markets Gazette.
- 3/5/2026NEGATIVEDon't Even Think About Buying Regencell Bioscience Stock Until You See This 1 Red Flag
The article warns investors against buying Regencell Bioscience stock (RGC), highlighting a critical "red flag." While the company is exploring Traditional Chinese Medicine (TCM) opportunities, the exact nature and viability of these ventures remain unclear. This lack of transparency or concrete details regarding Regencell Bioscience's TCM strategies poses a significant risk. For investors, this indicates high uncertainty and potential undisclosed issues, making the stock unsuitable for speculative investment until operational details and market potential are clarified.
- 3/1/2026NEGATIVEForget Regencell Bioscience: This Blue Chip Drug Maker Is the Boring Compounder You Need
A recent financial analysis article advises investors to disregard general market sentiment concerning Regencell Bioscience Holdings Limited. While not providing specific details, the analysis casts the company in an unfavorable light, suggesting to "forget" it in favor of an unspecified blue-chip drug maker, described as a "boring compounder" that investors need. This implies a cautious or negative outlook on Regencell, suggesting its prospects might not be as promising as market perception, or that more solid, less volatile alternatives exist. Investors should consider this as a potential red flag, prompting further due diligence on the company before making investment decisions.
via Markets Gazette